News
Release
![](xomalogonew2.jpg)
Paul
Goodson
Investor
Relations
Tel:
(510) 204-7270
www.xoma.com
XOMA
and Schering-Plough Establish
Collaboration for Therapeutic Antibody Discovery and
Development
********************************************************************
Berkeley,
California, May 23, 2006
- XOMA
Ltd (Nasdaq: XOMA) today announced the formation of a collaboration with
Schering-Plough Corporation (NYSE: SGP), through its research and development
arm, Schering-Plough Research Institute (SPRI), for therapeutic monoclonal
antibody discovery and development The collaboration is intended to capitalize
on XOMA’s comprehensive antibody discovery, development and production
technologies and expertise. Under the agreement, Schering-Plough will make
up-front and milestone payments to XOMA, fund XOMA’s R&D activities related
to the agreement, and pay royalties to XOMA on sales of products resulting
from
the collaboration. Additional financial terms were not disclosed.
Using
its
extensive collection of phage display libraries and optimization technologies,
XOMA will discover therapeutic antibodies against one or more targets selected
by SPRI. XOMA may also utilize its proprietary Human Engineering™
technology to humanize antibody candidates generated by hybridoma techniques.
Other XOMA activities will include pre-clinical studies to support regulatory
filings, cell line and process development, and production of antibodies for
initial clinical trials.
“With
our
collective capabilities and expertise, we plan to accelerate the discovery
and
development of therapeutic antibodies that meet or exceed key medical and
commercial design objectives,”
said
John
L.
Castello, President, Chairman and Chief Executive Officer of XOMA. “We look
forward to working together with Schering-Plough.”
About
XOMA
XOMA
is a
leader in the discovery, development and manufacture of therapeutic antibodies,
with a therapeutic focus that includes cancer and immune diseases.
The
company has built a premier antibody discovery and development platform that
includes access to seven of the leading commercially available antibody phage
display libraries and XOMA’s proprietary Human Engineering™ and bacterial cell
expression (BCE) technologies. More than 45 companies have signed BCE licenses.
As a leader in therapeutic antibodies, XOMA has established a unique and
comprehensive collection of technologies for antibody discovery, optimization,
development and production. With a fully integrated product development
infrastructure, XOMA’s product development capabilities extend from
preclini-
cal
sciences to product launch. For more information, please visit the company's
website at www.xoma.com.
Certain
statements contained herein concerning product development or that otherwise
relate to future periods are forward-looking statements within the meaning
of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These statements are based on assumptions that may not
prove accurate. Actual results could differ materially from those anticipated
due to certain risks inherent in the biotechnology industry and for companies
engaged in the development of new products in a regulated market. These risks,
including those related to the results of discovery research and preclinical
testing; the timing or results of pending and future clinical trials (including
the design and progress of clinical trials; safety and efficacy of the products
being tested; action, inaction or delay by the FDA, European or other regulators
or their advisory bodies; and analysis or interpretation by, or submission
to,
these entities or others of scientific data); uncertainties regarding the status
of biotechnology patents; uncertainties as to the cost of protecting
intellectual property; changes in the status of the existing collaborative
and
licensing relationships; the ability of collaborators, licensees and other
third
parties to meet their obligations; market demand for products; scale up and
marketing capabilities; competition; international operations; share price
volatility; XOMA’s financing needs and opportunities and risks associated with
XOMA’s status as a Bermuda company, are described in more detail in XOMA’s most
recent annual report on Form 10-K and in other SEC filings. Consider such risks
carefully in considering XOMA’s prospects.
-2-